$145.00 – $560.00
In Stock & Ready to Ship
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
| Clone | IHC058 |
| Source | Mouse Monoclonal |
| Positive Control | Squamous Cell Carcinoma of Lung |
| Dilution Range | 1:200 |
Annexin A1 (ANXA1) is a membrane protein that plays a role in innate and adaptive immunity by controlling the biosynthesis of inflammation, prostaglandins, and leukotriene mediators. This target is overexpressed in 97% of all samples from patients with with hairy cell leukemia, and is absent in other B-cell lymphomas. High ANXA1 expression is frequently associated with advanced stage esophageal and esophagogastric junction adenocarcinoma, and is also linked to advanced and metastatic disease states.
Cluster of differentiation 2 (CD2) is a useful early T-cell lineage restricted antigen that is present in T-cell differentiation. As a pan-T-cell marker, CD2 staining is used for recognizing practically all normal T-cells, but may be deleted in some T-cell neoplasms. Since CD2 is present in most precursor and mature T-cell leukemias and lymphomas, it is useful in the evaluation of lymphoid malignancies. By using CD2 and CD25 staining, the recognition of systemic mastocytosis and mastocytic leukemia is supported.
Isocitrate Dehydrogenase 1 (IDH1) is a soluble, cytosolic enzyme involved in the TCA metabolic cycle. The most notable mutation in this enzyme, R132H, is clinically indicated in the majority of astrocytomas and oligodendroglial tumours, with the mutation being associated with more favourable prognosis and increased survival in those patients. IDH1 R132H is also useful in the differential diagnosis between anaplastic glioma and glioblastoma.
CDX-2 is a caudal-related homeobox transcription factor that is expressed by intestinal epithelial cells. CDX-2 is a useful marker for gastrointestinal carcinoma, and for determining the origin of gastrointestinal metastatic adenocarcinoma and carcinoids. Anti-CDX-2 is used for differentiating lung and metastatic colorectal adenocarcinoma, however mucinous ovarian carcinoma also react positively with Anti-CDX-2, thereby limiting the ability to differentiate from metastatic colorectal adenocarcinoma.
